The DOI matches its Crossref record.
Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin
Abstract
Background— Low-molecular-weight heparin (LMWH) is recommended in the treatment of unstable angina (UA)/non–ST-segment–elevation myocardial infarction (NSTEMI), but no relationship has ever been shown between anticoagulation levels obtained with LMWH treatment and clinical outcomes. Methods and Results— In all, 803 consecutive patients with UA/NSTEMI were treated with subcutaneous enoxaparin and were followed up for 30 days. The recommended dose of enoxaparin of 1 mg/kg BID was used throughout the population except when physicians decided on dose reduction because of a history of a recent bleeding event or because of a high bleeding risk. Anti–factor Xa activity was >0.5 IU/mL in 93% of patients; subtherapeutic anti-Xa levels (<0.5 IU/mL) were associated with lower doses of enoxaparin. The 30-day mortality rate was significantly associated with low anti-Xa levels (<0.5 IU/mL), with a >3-fold increase in mortality compared with the patients with anti-Xa levels in the target range of 0.5 to 1.2 IU/mL ( P =0.004). Multivariate analysis revealed low anti-Xa activity as an independent predictor of 30-day mortality at least as strong as age, left ventricular function, and renal function. In contrast, anti-Xa activity did not predict major bleeding complications within the range of anti-Xa levels observed in this study. Conclusions— In this large unselected cohort of patients with UA/NSTEMI patients, low anti-Xa activity on enoxaparin treatment is independently associated with 30-day mortality, which highlights the need for achieving at least the minimum prescribed anti-Xa level of 0.5 IU/mL with enoxaparin whenever possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationAuthors/Task Force Members, Hamm, C. W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,080
Self-citationHamm, C. W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.006 · Cited by 1,068
Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency
Lim, W., Dentali, F., Eikelboom, J. W., & Crowther, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-9-200605020-00011 · Cited by 443
Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention
Montalescot, G., White, H. D., Gallo, R., Cohen, M., Steg, P. G., Aylward, P. E. G., Bode, C., Chiariello, M., King, S. B., Harrington, R. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052711 · Cited by 359
Self-citation
Metadata
- Authors
- Montalescot, G., Collet, J. P., Tanguy, M. L., Ankri, A., Payot, L., Dumaine, R., Choussat, R., Beygui, F., Gallois, V., & Thomas, D.
- Venue
- Circulation
- Published
- 2004-07-27
- Volume
- 110
- Issue
- 4
- Pages
- 392-398
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1990962878
- Cited by
- 163
- References
- 0
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin. https://app.cochat.ai/papers/10.1161/01.cir.0000136830.65073.c7
- The paper
- Montalescot, G., Collet, J. P., Tanguy, M. L., Ankri, A., Payot, L., Dumaine, R., Choussat, R., Beygui, F., Gallois, V., & Thomas, D. (2004). Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin. Circulation. https://doi.org/10.1161/01.cir.0000136830.65073.c7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.